HONG KONG -- Biotech startup Prenetics, a COVID-19 test provider that helped soccer's Premier League resume matches, is set to go public Wednesday on the Nasdaq, making it Hong Kong's first unicorn to list.
The market debut will see Prenetics absorbed by a New York-listed special purpose acquisition company backed by New World Development CEO Adrian Cheng in a deal that values the diagnostic testing business at $1.25 billion.
